AI Engines For more Details: Perplexity Kagi Labs You
Hypertension: Clonidine hydrochloride is commonly prescribed to lower blood pressure in individuals with hypertension. It works by stimulating alpha-2 adrenergic receptors in the brainstem, which leads to decreased sympathetic outflow from the central nervous system. This results in reduced peripheral vascular resistance, heart rate, and blood pressure. Clonidine hydrochloride may be used alone or in combination with other antihypertensive medications to achieve target blood pressure levels.
Attention Deficit Hyperactivity Disorder (ADHD): Clonidine hydrochloride is sometimes used off-label to treat ADHD, particularly in children who cannot tolerate or do not respond adequately to stimulant medications. It can help improve symptoms such as hyperactivity, impulsivity, and inattention by modulating certain neurotransmitter systems in the brain. Clonidine hydrochloride may be used as monotherapy or as an adjunct to other ADHD medications.
Opioid Withdrawal: Clonidine hydrochloride is also used off-label to manage symptoms of opioid withdrawal in individuals undergoing detoxification or maintenance therapy for opioid addiction. It can help alleviate symptoms such as anxiety, agitation, sweating, diarrhea, and drug cravings by reducing sympathetic nervous system activity. Clonidine hydrochloride may be used as part of a comprehensive opioid withdrawal management program, along with other medications and supportive therapies.
Anxiety Disorders: Clonidine hydrochloride may have anxiolytic (anti-anxiety) effects in certain individuals and may be used off-label to manage symptoms of anxiety disorders such as generalized anxiety disorder (GAD) or panic disorder. It works by reducing sympathetic nervous system activity and modulating the release of certain neurotransmitters involved in the stress response. Clonidine hydrochloride may be used alone or in combination with other anxiolytic medications or psychotherapy.
Tourette Syndrome: Clonidine hydrochloride is sometimes used off-label to manage symptoms of Tourette syndrome, a neurological disorder characterized by involuntary motor and vocal tics. It may help reduce the frequency and severity of tics by modulating neurotransmitter activity in the brain. Clonidine hydrochloride may be used as adjunctive therapy to other medications or behavioral interventions for Tourette syndrome.
Menopausal Symptoms: Clonidine hydrochloride may be used off-label to alleviate certain symptoms of menopause, such as hot flashes and night sweats. It may help regulate body temperature and reduce the frequency and severity of vasomotor symptoms associated with hormonal fluctuations during menopause. Clonidine hydrochloride may be used as an alternative to hormone replacement therapy (HRT) in women who cannot or prefer not to use estrogen-based treatments.
Sleep Disorders: Clonidine hydrochloride may be used off-label to improve sleep quality and duration in individuals with certain sleep disorders, such as insomnia or sleep disturbances associated with ADHD or opioid withdrawal. It may help promote sleep by reducing arousal and increasing relaxation through its effects on the central nervous system. Clonidine hydrochloride may be used as adjunctive therapy to other sleep medications or behavioral interventions.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | 0.3 | |
| ADHD | 1.1 | 0.3 | 2.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 0.9 | 0.7 | 0.29 |
| Allergies | 1.5 | 0.9 | 0.67 |
| Allergy to milk products | 1.3 | 0.6 | 1.17 |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 2 | 2.2 | -0.1 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.9 | 0.7 | 0.29 |
| Ankylosing spondylitis | 1.6 | 0.3 | 4.33 |
| Anorexia Nervosa | 0.6 | 1.1 | -0.83 |
| Antiphospholipid syndrome (APS) | 0.7 | 0.3 | 1.33 |
| Asthma | 1.9 | 0.9 | 1.11 |
| Atherosclerosis | 1 | 0.8 | 0.25 |
| Atrial fibrillation | 0.9 | 0.9 | 0 |
| Autism | 2.5 | 2.9 | -0.16 |
| Autoimmune Disease | 0.9 | 0.5 | 0.8 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.6 | 0.6 | |
| Biofilm | 0.7 | 0.7 | |
| Bipolar Disorder | 1.2 | 1.1 | 0.09 |
| Brain Trauma | 0.6 | 0.8 | -0.33 |
| Breast Cancer | 0.7 | 0.3 | 1.33 |
| Carcinoma | 1.8 | 0.6 | 2 |
| Celiac Disease | 0.9 | 0.6 | 0.5 |
| Cerebral Palsy | 0.3 | 0.8 | -1.67 |
| Chronic Fatigue Syndrome | 1.3 | 1.3 | 0 |
| Chronic Kidney Disease | 0.9 | 1.4 | -0.56 |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.6 | 1.1 | 0.45 |
| Chronic Urticaria (Hives) | 1.3 | 0 | 0 |
| Coagulation / Micro clot triggering bacteria | 1.3 | 1.1 | 0.18 |
| Cognitive Function | 1.4 | 0.8 | 0.75 |
| Colorectal Cancer | 3.9 | 1.8 | 1.17 |
| Constipation | 1.1 | 0.8 | 0.38 |
| Coronary artery disease | 1.9 | 0.8 | 1.37 |
| COVID-19 | 2 | 2.9 | -0.45 |
| Crohn's Disease | 3.2 | 1.5 | 1.13 |
| Cushing's Syndrome (hypercortisolism) | 0.2 | -0.2 | |
| cystic fibrosis | 1 | 0.5 | 1 |
| d-lactic acidosis (one form of brain fog) | 0.4 | 0.4 | |
| deep vein thrombosis | 2.1 | 1.1 | 0.91 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 3.8 | 3.3 | 0.15 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.9 | 0.9 | 0 |
| Endometriosis | 1.6 | 1.5 | 0.07 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 1.6 | 0 | 0 |
| erectile dysfunction | 0.6 | 0.6 | |
| Fibromyalgia | 0.5 | 0.1 | 4 |
| Functional constipation / chronic idiopathic constipation | 2.1 | 1.1 | 0.91 |
| gallstone disease (gsd) | 1.3 | 0.6 | 1.17 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.3 | -0.5 |
| Generalized anxiety disorder | 1.6 | 1.1 | 0.45 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.6 | 0 |
| Graves' disease | 0.6 | 1.7 | -1.83 |
| Gulf War Syndrome | 0.6 | 0 | 0 |
| Halitosis | 0.3 | 0.3 | 0 |
| Hashimoto's thyroiditis | 0.9 | 0.3 | 2 |
| Heart Failure | 1.9 | 0.9 | 1.11 |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.9 | 0.3 | 2 |
| hypercholesterolemia (High Cholesterol) | 0.4 | 0 | 0 |
| hyperglycemia | 2.2 | 0 | 0 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 1.5 | 1.7 | -0.13 |
| Hypothyroidism | 0 | 0.3 | 0 |
| Hypoxia | 1 | 1 | |
| IgA nephropathy (IgAN) | 0.6 | 0.5 | 0.2 |
| Inflammatory Bowel Disease | 2.4 | 2.5 | -0.04 |
| Insomnia | 1.5 | 1.2 | 0.25 |
| Intelligence | 0.7 | 0.7 | |
| Intracranial aneurysms | 0.3 | 0.6 | -1 |
| Irritable Bowel Syndrome | 2.4 | 1.9 | 0.26 |
| ischemic stroke | 1 | 1.1 | -0.1 |
| Liver Cirrhosis | 3.3 | 2.7 | 0.22 |
| Long COVID | 1.5 | 2.2 | -0.47 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.9 | 0.3 | 2 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 0.9 | 0.6 | 0.5 |
| ME/CFS with IBS | 0.3 | 0.1 | 2 |
| ME/CFS without IBS | 0.3 | 0.3 | |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.6 | -1 |
| Metabolic Syndrome | 3.3 | 1.9 | 0.74 |
| Mood Disorders | 3.2 | 2.7 | 0.19 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.9 | |
| Multiple Sclerosis | 2.6 | 1.4 | 0.86 |
| Multiple system atrophy (MSA) | 0 | 0.3 | 0 |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 0.6 | -0.6 | |
| Neuropathy (all types) | 0.3 | 1.4 | -3.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.4 | 1.2 | 1 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | |
| Obesity | 3.8 | 3 | 0.27 |
| obsessive-compulsive disorder | 1.8 | 0.6 | 2 |
| Osteoarthritis | 0.9 | 0.6 | 0.5 |
| Osteoporosis | 1.4 | 0.3 | 3.67 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 4.5 | 2 | 1.25 |
| Polycystic ovary syndrome | 2.5 | 1.7 | 0.47 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.3 | 0.3 | |
| primary biliary cholangitis | 0.3 | 0.6 | -1 |
| Primary sclerosing cholangitis | 0.3 | 0.6 | -1 |
| Psoriasis | 1.2 | 0.9 | 0.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.1 | 1.1 | 1.82 |
| Rosacea | 0.3 | 0.5 | -0.67 |
| Schizophrenia | 1.5 | 1.1 | 0.36 |
| scoliosis | 0.7 | 0.6 | 0.17 |
| Sjögren syndrome | 0.9 | 0.9 | |
| Sleep Apnea | 0.6 | 1.1 | -0.83 |
| Slow gastric motility / Gastroparesis | 0.7 | 0.7 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1 | 1 | |
| Stress / posttraumatic stress disorder | 0.9 | 1.1 | -0.22 |
| Systemic Lupus Erythematosus | 1.5 | 0.8 | 0.88 |
| Tic Disorder | 0.8 | 0.3 | 1.67 |
| Tourette syndrome | 0.3 | 0.3 | |
| Type 1 Diabetes | 2 | 1.3 | 0.54 |
| Type 2 Diabetes | 3.7 | 2.3 | 0.61 |
| Ulcerative colitis | 1.5 | 1.7 | -0.13 |
| Unhealthy Ageing | 1.1 | 0.8 | 0.38 |
| Vitiligo | 0.6 | 0.1 | 5 |
